BridgeBio Strikes U.S. Government Deal to Expand Attruby Access Without Pricing Mandates
BBIO sits 57% above its 52-week low of $48.78 on light trading volume (0.4× avg).
Summary
BridgeBio announced an agreement with the U.S. government to improve affordability and access to its critical medicines, specifically expanding state Medicaid access to Attruby and offering it via Medicare Part D without future pricing mandates. The deal does not impact the ForgingBridges copay assistance program, and terms remain confidential. This is a significant commercial development for Attruby, which generated $222M in Q2 revenue, as it removes a major reimbursement uncertainty and could broaden patient access. The agreement follows recent positive Phase 3 data presented at ESC Congress and comes amid heavy insider selling by Viking Global and KKR. Investors will watch for any disclosure of financial terms or volume commitments in future filings.
At the time of this announcement, BBIO was trading at $76.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.9B. The 52-week trading range was $48.78 to $93.42. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.